2026-06956Presidential DocumentWallet

White House Targets Foreign Drug Imports to Boost U.S. Security

Published Date: 4/9/2026

Presidential Document

Summary

The U.S. government found that relying too much on imported medicines and their key ingredients could hurt national security and health. To fix this, new rules will adjust how patented pharmaceuticals and their ingredients come into the country, aiming to boost U.S. production and protect access to vital medicines. These changes will start soon and could impact companies importing these drugs, encouraging more domestic manufacturing.

Analyzed Economic Effects

9 provisions identified: 4 benefits, 4 costs, 1 mixed.

100% Tariff on Patented Pharmaceuticals

The proclamation imposes a 100 percent ad valorem duty on imports of patented pharmaceuticals and associated pharmaceutical ingredients identified in Annex I. This duty applies unless a different rate or exemption in the proclamation applies.

Lower Tariff for Companies With Onshoring Plans

Products from companies that have Secretary-approved onshoring plans are subject to a 20 percent ad valorem duty rate, with that 20 percent rising to 100 percent on April 2, 2030 (four years after the proclamation). The Secretary will approve, monitor, and enforce onshoring plans and require periodic reports and possible audits.

Zero Tariff for MFN Pricing / Onshoring Agreement Companies

Companies that have fully executed agreements or are negotiating agreements with the Secretary and the Secretary of Health and Human Services regarding Most-Favored-Nation (MFN) pricing and onshoring may receive a zero ad valorem tariff rate. The proclamation specifies that such zero tariff treatment applies until January 20, 2029 for eligible companies.

Country-Specific Reduced Tariff Rates

The proclamation sets lower ad valorem rates by origin: 15 percent for products of Japan, the European Union, the Republic of Korea, and Switzerland and Liechtenstein (jointly), and 10 percent for products of the United Kingdom (with the UK rate subject to reduction to zero under a future agreement).

Exemptions for Critical and Specialty Medicines

The proclamation exempts from these tariffs (zero rate) drugs where all approved indications are orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, medical countermeasures for CBRN threats, other specialty pharmaceuticals identified by the Secretary, and animal health products when certain conditions are met. The Secretary must publish a Federal Register notice when making such determinations.

Generics and Biosimilars Excluded from Tariffs

Generic pharmaceuticals, biosimilars, and their associated ingredients (including purchases for the Strategic API Reserve) will not be subject to section 232 tariffs at this time. The Secretary will review and report within one year on whether circumstances indicate the need for action on generics.

Effective Dates for Tariff Implementation

Tariff treatment under the proclamation becomes effective for entries on or after 12:01 a.m. EDT on July 31, 2026 for companies listed in Annex III and on or after September 29, 2026 for other companies. Tariffs continue in effect unless reduced, modified, or terminated.

Enforcement, Onshoring Criteria, and Retroactive Penalties

The Secretary will publish onshoring-plan criteria in the Federal Register, require periodic (and possibly audited) progress reports, monitor compliance, and may reimpose tariffs prospectively and retroactively or impose other penalties if the executive branch assesses fraud or deliberate misleading by companies about onshoring commitments.

Drawback, U.S.-Origin Exemption, and Customs Rules

Drawback (duty refund) is available for duties imposed by this proclamation, and imports of U.S.-origin pharmaceutical products are not subject to the proclamation's tariffs at this time. Customs and Border Protection may require information and take measures to administer the tariffs.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Effective Date
4/9/2026
7/31/2026

Department and Agencies

Department
Independent Agency
Agency
Executive Office of the President
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register